COMMUNIQUÉS West-GlobeNewswire

Spectral AI Announces 2026 First Quarter Financial Results
12/05/2026
Development Work for DeepView ® Systems Continues with Support of Recently Awarded $31.7 Million of Funding from BARDA Reiterates Annual Revenues Guidance DALLAS, May 12, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. ( [...]
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
12/05/2026
- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug [...]
Lumexa Imaging Announces First Quarter 2026 Results
12/05/2026
RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced results for the first quarter ended March 31, 2026, [...]
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
12/05/2026
Q1 Revenue of $9.0 million Q1 Income from Continuing Operations of $0.8 million Q1 Thyroid volume year-over-year increase of 10% Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE [...]
Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates
12/05/2026
Proprietary robotically-navigated MAGiC catheter received U.S. FDA approval in January and is now being utilized at multiple sites across the United States as well as Europe Synchrony digital operating room system [...]
Nyxoah Reports First Quarter 2026 Financial and Operating Results
12/05/2026
REGULATED INFORMATION Nyxoah Reports First Quarter 2026 Financial and Operating Results Strong Genio launch in the U.S. drove 25% sequential quarterly U.S. revenue growth Continued clarity around HGNS and Genio [...]
Nyxoah Publie ses Résultats Financiers et Opérationnels du Premier Trimestre 2026
12/05/2026
INFORMATIONS RÉGLEMENTÉES Nyxoah Publie ses Résultats Financiers et Opérationnels du Premier Trimestre 2026 Le lancement réussi de Genio aux États-Unis génère une croissance trimestrielle séquentielle de 25 % du chiffre [...]
TELA Bio Reports First Quarter 2026 Financial Results
12/05/2026
MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial [...]
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
12/05/2026
Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1 trial of LB-102 in [...]
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
12/05/2026
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the [...]
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into [...]
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/05/2026
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Surrozen to Present at Upcoming Healthcare Investor Conference
12/05/2026
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling [...]
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
12/05/2026
BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein [...]
Lumexa Imaging Advances Growth Strategy by Adding Four New Imaging Centers
12/05/2026
Expansion across the Southeast and Mid-Atlantic includes entry into Pennsylvania through joint venture with University of Pittsburgh Medical Center (UPMC) RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging ( [...]
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
12/05/2026
Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all [...]
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
12/05/2026
Data presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible [...]
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
12/05/2026
Next anticipated Revita ® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 Early Q4 2026 timing for topline 6-month [...]
Lifecore Biomedical to Participate at CDMO Live Europe
12/05/2026
CHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that [...]

Pages